Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
BMC Pregnancy Childbirth ; 22(1): 905, 2022 Dec 05.
Article in English | MEDLINE | ID: covidwho-2153540

ABSTRACT

BACKGROUND: In low- and middle-income countries, pregnant women and newborns are more vulnerable to adverse outcomes from coronavirus disease 2019 (COVID-19). However, in Venezuela, there are no integrated data in a national surveillance system to identify the clinical-epidemiological characteristics and maternal-foetal outcomes of pregnant women hospitalised with COVID-19. METHODS: A retrospective study was conducted among Venezuelan pregnant women hospitalised with COVID-19 seen at the "Ruiz y Páez" University Hospital Complex and the San Cristobal Central Hospital between June 2020 and September 2021. Information was obtained from physical and digitised clinical records using a purpose-designed proforma to collect epidemiological, clinical, paraclinical, treatment, obstetric and perinatal complications, and maternal-foetal outcomes data. RESULTS: A total of 80 pregnant women with confirmed severe acute respiratory syndrome coronavirus 2 infection were seen within the study period, 59 (73.8%) survived and 21 (26.2%) died. The median (interquartile range) age was 29 (23-33) years, the majority being in the third trimester of pregnancy (81.2%; n = 65). Interestingly, four (5%) pregnant women were co-infected with malaria by Plasmodium vivax and three (3.8%) with syphilis. The most frequent symptoms were fever (75%; n = 60), dry cough (68.8%; n = 55), dyspnoea (55%; n = 44), and headache (53.8%; n = 43). The most frequent maternal complications were anaemia (51.5%; n = 66) and hypertensive disorders of pregnancy (17.5%; n = 14). The most frequent perinatal complications were preterm delivery (39.2%; n = 20/51) and oligohydramnios (31.3%; n = 25). A total of 29 (36.3%) adverse foetal outcomes were documented, 21 stillbirth and eight abortions. CONCLUSION: This is the first study to describe the clinical-epidemiological behaviour of COVID-19 in hospitalised Venezuelan pregnant women. Anaemia, hypertensive disorders of pregnancy, oligohydramnios, and low birth weight were the most frequent maternal-foetal complications in this population of pregnant women.


Subject(s)
Anemia , COVID-19 , Hypertension, Pregnancy-Induced , Oligohydramnios , Pregnancy Complications, Infectious , Premature Birth , Infant, Newborn , Female , Pregnancy , Humans , Adult , COVID-19/epidemiology , Retrospective Studies , Pregnancy Complications, Infectious/epidemiology , Pregnant Women , Venezuela/epidemiology , Premature Birth/epidemiology , Stillbirth/epidemiology , Anemia/epidemiology , Pregnancy Outcome/epidemiology
2.
Clinics (Sao Paulo) ; 77: 100073, 2022.
Article in English | MEDLINE | ID: covidwho-1906899

ABSTRACT

OBJECTIVES: To determine the incidence and risk of adverse obstetric and neonatal outcomes according to SARS-CoV-2 infection severity in pregnant women. METHOD: Open prospective study of pregnant women tested for SARS-CoV-2 by serological and molecular assays during pregnancy or delivery in two hospitals in Sao Paulo, Brazil from April 12, 2020, to February 28, 2021. Five groups were considered for analysis: C0, negative COVID-19 results and no COVID-19 symptoms; C1, positive COVID-19 results, and no symptoms; C2, positive COVID-19 results with mild symptoms; C3, positive COVID-19 results with moderate symptoms; and C4, positive COVID-19 results with severe symptoms. The association between obstetric and neonatal outcomes and COVID-19 severity was determined using multivariate analysis. RESULTS: 734 eligible pregnant women were enrolled as follows: C0 (n = 357), C1 (n = 127), C2 (n = 174), C3 (n = 37), and C4 (n = 39). The following pregnancy and neonatal outcomes were associated with severe COVID-19: oligohydramnios (adjusted Odds Ratio [aOR] = 6.18; 95% CI 1.87‒20.39), fetal distress (aOR = 4.01; 95% Confidence Interval [CI] 1.84‒8.75), preterm birth (aOR = 5.51; 95% CI 1.47‒20.61), longer hospital stay (aOR = 1.66; 95% CI 1.36‒2.02), and admission to the neonatal intensive care unit (aOR = 19.36; 95% CI, 5.86‒63.99). All maternal (n = 6, 15.4%, p < 0.001) and neonatal (n = 5, 12.5%, p < 0.001) deaths and most fetal deaths (n = 4, 9.8%, p < 0.001) occurred in C4 group. Moderate COVID-19 was associated with oligohydramnios (aOR = 6.23; 95% CI 1.93‒20.13) and preterm birth (aOR = 3.60; 95% CI 1.45‒9.27). Mild COVID-19 was associated with oligohydramnios (aOR = 3.77; 95% CI 1.56‒9.07). CONCLUSION: Adverse pregnancy and neonatal outcomes were associated with maternal symptomatic COVID-19 status, and risk increased with disease severity.


Subject(s)
COVID-19 , Oligohydramnios , Pregnancy Complications, Infectious , Premature Birth , Brazil , Female , Humans , Infant, Newborn , Pregnancy , Pregnancy Outcome , Pregnant Women , Prospective Studies , SARS-CoV-2
4.
researchsquare; 2021.
Preprint in English | PREPRINT-RESEARCHSQUARE | ID: ppzbmed-10.21203.rs.3.rs-772124.v1

ABSTRACT

The ongoing pandemic of COVID-19 disease has adverse effects on both pregnant women and their fetuses. However the literature about the effects of this disease on placenta and its clinical implication is limited. Here we report two cases of severe oligohydramnios detected in asymptomatic patients with covid infection. In both of our patients, severe oligohydramnios was detected during routine antenatal check up in third trimester of pregnancy. Both the patients underwent cesarean delivery and delivered healthy neonates. The onset of oligohydramnios was noticed to be very fast and not associated with severity of symptoms of Covid-19 infection. It is recommended for increase in number of ultrasound examination in pregnant women positive for covid-19 infection in view of our findings.


Subject(s)
COVID-19 , Oligohydramnios
6.
BMC Pregnancy Childbirth ; 20(1): 481, 2020 Aug 24.
Article in English | MEDLINE | ID: covidwho-727268

ABSTRACT

BACKGROUND: The world's understanding of COVID-19 continues to evolve as the scientific community discovers unique presentations of this disease. This case report depicts an unexpected intraoperative coagulopathy during a cesarean section in an otherwise asymptomatic patient who was later found to have COVID-19. This case suggests that there may be a higher risk for intrapartum bleeding in the pregnant, largely asymptomatic COVID-positive patient with more abnormal COVID laboratory values. CASE: The case patient displayed D-Dimer elevations beyond what is typically observed among this hospital's COVID-positive peripartum population and displayed significantly more oozing than expected intraoperatively, despite normal prothrombin time, international normalized ratio, fibrinogen, and platelets. CONCLUSION: There is little published evidence on the association between D-Dimer and coagulopathy among the pregnant population infected with SARS-CoV-2. This case report contributes to the growing body of evidence on the effects of COVID-19 in pregnancy. A clinical picture concerning for intraoperative coagulopathy may be associated with SARS-CoV-2 infection during cesarean sections, and abnormal COVID laboratory tests, particularly D-Dimer, may help identify the patients in which this presentation occurs.


Subject(s)
Blood Coagulation Disorders/blood , Blood Loss, Surgical , Breech Presentation/surgery , Cesarean Section , Coronavirus Infections/blood , Pneumonia, Viral/blood , Pregnancy Complications, Hematologic/blood , Pregnancy Complications, Infectious/blood , Adult , Antifibrinolytic Agents/therapeutic use , Betacoronavirus , Blood Coagulation Disorders/drug therapy , Blood Coagulation Disorders/metabolism , C-Reactive Protein/metabolism , COVID-19 , Cautery , Coronavirus Infections/diagnosis , Coronavirus Infections/metabolism , Female , Fibrin Fibrinogen Degradation Products/metabolism , Fibrinogen/metabolism , Hemostasis, Surgical , Humans , International Normalized Ratio , Methylergonovine/therapeutic use , Oligohydramnios , Oxytocics/therapeutic use , Oxytocin/therapeutic use , Pandemics , Platelet Count , Pneumonia, Viral/diagnosis , Pneumonia, Viral/metabolism , Pregnancy , Pregnancy Complications, Hematologic/drug therapy , Pregnancy Complications, Hematologic/metabolism , Pregnancy Complications, Infectious/diagnosis , Pregnancy Complications, Infectious/metabolism , Prothrombin Time , SARS-CoV-2 , Tranexamic Acid/therapeutic use , Uterine Inertia/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL